Patient characteristics by genetic test result
| . | Positive (n = 5) . | Negative (n = 35) . | VUS (n = 34) . | Total (N = 74) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 5 (11.4%) | 18 (40.9%) | 21 (47.7%) | 44 (100.0%) |
| Female | 0 (0.0%) | 17 (56.7%) | 13 (43.3%) | 30 (100.0%) |
| Age, y | ||||
| Mean (SD) | 58.8 (13.5) | 58.9 (11.5) | 58.3 (12.4) | 58.6 (11.9) |
| Median | 64.0 | 63.0 | 62.0 | 63.0 |
| Range | 44.0-76.0 | 29.0-78.0 | 25.0-78.0 | 25.0-78.0 |
| Age (group) | ||||
| Age <50 y | 2 (11.1%) | 8 (44.4%) | 8 (44.4%) | 18 (100.0%) |
| Age ≥50 y | 3 (5.4%) | 27 (48.2%) | 26 (46.4%) | 56 (100.0%) |
| Race/ethnicity | ||||
| White | 5 (8.2%) | 29 (47.5%) | 27 (44.3%) | 61 (100.0%) |
| Hispanic/Latino | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) |
| Black/African American | 0 (0.0%) | 2 (40.0%) | 3 (60.0%) | 5 (100.0%) |
| Asian | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) | 2 (100.0%) |
| American Indian/Alaskan Native | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) | 3 (100.0%) |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 | 0 |
| Other | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) |
| Race (dichotomized) | ||||
| White | 5 (8.2%) | 29 (47.5%) | 27 (44.3%) | 61 (100.0%) |
| Non-White | 0 (0.0%) | 6 (46.2%) | 7 (53.8%) | 13 (100.0%) |
| Ethnicity | ||||
| Hispanic/Latino | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) |
| Non-Hispanic | 5 (6.9%) | 34 (47.2%) | 33 (45.8%) | 72 (100.0%) |
| Body mass index >30 | ||||
| Yes | 5 (12.5%) | 21 (52.5%) | 14 (35.0%) | 40 (100.0%) |
| No | 0 (0.0%) | 11 (37.9%) | 18 (62.1%) | 29 (100.0%) |
| Missing | 0 | 3 | 2 | 5 |
| R-ISS stage | ||||
| Stage I | 1 (14.3%) | 4 (57.1%) | 2 (28.6%) | 7 (100.0%) |
| Stage II | 1 (3.4%) | 13 (44.8%) | 15 (51.7%) | 29 (100.0%) |
| Stage III | 0 (0.0%) | 5 (35.7%) | 9 (64.3%) | 14 (100.0%) |
| Missing | 3 | 13 | 8 | 24 |
| High-risk translocation or CNA | ||||
| Yes | 1 (7.1%) | 7 (50.0%) | 6 (42.9%) | 14 (100.0%) |
| No | 3 (5.4%) | 26 (46.4%) | 27 (48.2%) | 56 (100.0%) |
| Missing | 1 | 2 | 1 | 4 |
| Family history of hematologic malignancy | ||||
| Yes | 1 (6.7%) | 9 (60.0%) | 5 (33.3%) | 15 (100.0%) |
| No/unknown | 4 (6.8%) | 26 (44.1%) | 29 (49.2%) | 59 (100.0%) |
| Family history of cancer | ||||
| Yes | 3 (8.1%) | 18 (48.6%) | 16 (43.2%) | 37 (100.0%) |
| No/unknown | 2 (5.6%) | 16 (44.4%) | 18 (50.0%) | 36 (100.0%) |
| Missing | 0 | 1 | 0 | 1 |
| Transplant status | ||||
| Yes | 5 (10.0%) | 22 (44.0%) | 23 (46.0%) | 50 (100.0%) |
| No | 0 (0.0%) | 12 (52.2%) | 11 (47.8%) | 23 (100.0%) |
| Missing | 0 | 1 | 0 | 1 |
| Seq FISH (percent “yes” for each category) | ||||
| t(11;14) | 0 (0.0%) | 5 (55.6%) | 4 (44.4%) | 9 (100.0%) |
| Del(17p) | 1 (9.1%) | 4 (36.4%) | 6 (54.5%) | 11 (100.0%) |
| Gain 1q | 1 (5.6%) | 6 (33.3%) | 11 (61.1%) | 18 (100.0%) |
| t(4;14) | 1 (20.0%) | 2 (40.0%) | 2 (40.0%) | 5 (100.0%) |
| t(14;16) | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) | 2 (100.0%) |
| t(14;20) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Intensity of frontline therapy (no. of therapies) | ||||
| 2 | 0 (0.0%) | 4 (44.4%) | 5 (55.6%) | 9 (100.0%) |
| 3 | 4 (7.7%) | 24 (46.2%) | 24 (46.2%) | 52 (100.0%) |
| 4 | 0 (0.0%) | 3 (50.0%) | 3 (50.0%) | 6 (100.0%) |
| Missing | 1 | 4 | 2 | 7 |
| Deceased | ||||
| Yes | 0 (0.0%) | 2 (18.2%) | 9 (81.8%) | 11 (100.0%) |
| No | 5 (8.1%) | 32 (51.6%) | 25 (40.3%) | 62 (100.0%) |
| Missing | 0 | 1 | 0 | 1 |
| Follow-up time (mo) | ||||
| Mean (SD) | 101.7 (146.3) | 46.4 (28.2) | 53.0 (37.5) | 53.3 (48.8) |
| Median | 37.4 | 44.4 | 42.3 | 42.3 |
| Range | 29.1-363.3 | 2.8-126.4 | 7.7-176.0 | 2.8-363.3 |
| . | Positive (n = 5) . | Negative (n = 35) . | VUS (n = 34) . | Total (N = 74) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 5 (11.4%) | 18 (40.9%) | 21 (47.7%) | 44 (100.0%) |
| Female | 0 (0.0%) | 17 (56.7%) | 13 (43.3%) | 30 (100.0%) |
| Age, y | ||||
| Mean (SD) | 58.8 (13.5) | 58.9 (11.5) | 58.3 (12.4) | 58.6 (11.9) |
| Median | 64.0 | 63.0 | 62.0 | 63.0 |
| Range | 44.0-76.0 | 29.0-78.0 | 25.0-78.0 | 25.0-78.0 |
| Age (group) | ||||
| Age <50 y | 2 (11.1%) | 8 (44.4%) | 8 (44.4%) | 18 (100.0%) |
| Age ≥50 y | 3 (5.4%) | 27 (48.2%) | 26 (46.4%) | 56 (100.0%) |
| Race/ethnicity | ||||
| White | 5 (8.2%) | 29 (47.5%) | 27 (44.3%) | 61 (100.0%) |
| Hispanic/Latino | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) |
| Black/African American | 0 (0.0%) | 2 (40.0%) | 3 (60.0%) | 5 (100.0%) |
| Asian | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) | 2 (100.0%) |
| American Indian/Alaskan Native | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) | 3 (100.0%) |
| Native Hawaiian/Pacific Islander | 0 | 0 | 0 | 0 |
| Other | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) |
| Race (dichotomized) | ||||
| White | 5 (8.2%) | 29 (47.5%) | 27 (44.3%) | 61 (100.0%) |
| Non-White | 0 (0.0%) | 6 (46.2%) | 7 (53.8%) | 13 (100.0%) |
| Ethnicity | ||||
| Hispanic/Latino | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) |
| Non-Hispanic | 5 (6.9%) | 34 (47.2%) | 33 (45.8%) | 72 (100.0%) |
| Body mass index >30 | ||||
| Yes | 5 (12.5%) | 21 (52.5%) | 14 (35.0%) | 40 (100.0%) |
| No | 0 (0.0%) | 11 (37.9%) | 18 (62.1%) | 29 (100.0%) |
| Missing | 0 | 3 | 2 | 5 |
| R-ISS stage | ||||
| Stage I | 1 (14.3%) | 4 (57.1%) | 2 (28.6%) | 7 (100.0%) |
| Stage II | 1 (3.4%) | 13 (44.8%) | 15 (51.7%) | 29 (100.0%) |
| Stage III | 0 (0.0%) | 5 (35.7%) | 9 (64.3%) | 14 (100.0%) |
| Missing | 3 | 13 | 8 | 24 |
| High-risk translocation or CNA | ||||
| Yes | 1 (7.1%) | 7 (50.0%) | 6 (42.9%) | 14 (100.0%) |
| No | 3 (5.4%) | 26 (46.4%) | 27 (48.2%) | 56 (100.0%) |
| Missing | 1 | 2 | 1 | 4 |
| Family history of hematologic malignancy | ||||
| Yes | 1 (6.7%) | 9 (60.0%) | 5 (33.3%) | 15 (100.0%) |
| No/unknown | 4 (6.8%) | 26 (44.1%) | 29 (49.2%) | 59 (100.0%) |
| Family history of cancer | ||||
| Yes | 3 (8.1%) | 18 (48.6%) | 16 (43.2%) | 37 (100.0%) |
| No/unknown | 2 (5.6%) | 16 (44.4%) | 18 (50.0%) | 36 (100.0%) |
| Missing | 0 | 1 | 0 | 1 |
| Transplant status | ||||
| Yes | 5 (10.0%) | 22 (44.0%) | 23 (46.0%) | 50 (100.0%) |
| No | 0 (0.0%) | 12 (52.2%) | 11 (47.8%) | 23 (100.0%) |
| Missing | 0 | 1 | 0 | 1 |
| Seq FISH (percent “yes” for each category) | ||||
| t(11;14) | 0 (0.0%) | 5 (55.6%) | 4 (44.4%) | 9 (100.0%) |
| Del(17p) | 1 (9.1%) | 4 (36.4%) | 6 (54.5%) | 11 (100.0%) |
| Gain 1q | 1 (5.6%) | 6 (33.3%) | 11 (61.1%) | 18 (100.0%) |
| t(4;14) | 1 (20.0%) | 2 (40.0%) | 2 (40.0%) | 5 (100.0%) |
| t(14;16) | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) | 2 (100.0%) |
| t(14;20) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Intensity of frontline therapy (no. of therapies) | ||||
| 2 | 0 (0.0%) | 4 (44.4%) | 5 (55.6%) | 9 (100.0%) |
| 3 | 4 (7.7%) | 24 (46.2%) | 24 (46.2%) | 52 (100.0%) |
| 4 | 0 (0.0%) | 3 (50.0%) | 3 (50.0%) | 6 (100.0%) |
| Missing | 1 | 4 | 2 | 7 |
| Deceased | ||||
| Yes | 0 (0.0%) | 2 (18.2%) | 9 (81.8%) | 11 (100.0%) |
| No | 5 (8.1%) | 32 (51.6%) | 25 (40.3%) | 62 (100.0%) |
| Missing | 0 | 1 | 0 | 1 |
| Follow-up time (mo) | ||||
| Mean (SD) | 101.7 (146.3) | 46.4 (28.2) | 53.0 (37.5) | 53.3 (48.8) |
| Median | 37.4 | 44.4 | 42.3 | 42.3 |
| Range | 29.1-363.3 | 2.8-126.4 | 7.7-176.0 | 2.8-363.3 |
Percentages are calculated by row.
FISH, fluorescence in situ hybridization; SD, standard deviation; Seq, Sequence; VUS, variant of unknown significance.